PPIDT00259
Drug Information
| Name | Blinatumomab |
|---|---|
| Sequence | DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH |
| DrugBank_ID | DB09052 |
| Type | biotech |
| Indication | Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.[L46991] When used in the consolidation phase of a multi-phase chemotherapy regimen, blinatumomab is also indicated for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL).[L51088] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution | Intravenous |
38.5 mcg/1vial
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
12.5 ug/1mL
|
| Powder | Intravenous; Parenteral |
38.5 MICROGRAMMI
|
| Powder, for solution | Intravenous |
38.5 mcg / vial
|
| Solution | Intravenous |
38.5 mcg
|
| Injection | Intravenous |
35 ug
|
| Injection | Parenteral |
38.5 mcg
|
| Injection, powder, lyophilized, for solution | Intravenous |
55 mcg/ml
|
| Injection, powder, lyophilized, for solution | Intravenous |
3850000 mcg
|